11/26
02:13 pm
pen
Penumbra (NYSE:PEN) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Penumbra (NYSE:PEN) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
04:30 pm
pen
Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
11/18
10:20 am
pen
Penumbra (NYSE:PEN) is now covered by analysts at Wells Fargo & Company. They set an "underweight" rating and a $15.00 price target on the stock.
Low
Report
Penumbra (NYSE:PEN) is now covered by analysts at Wells Fargo & Company. They set an "underweight" rating and a $15.00 price target on the stock.
11/11
07:08 pm
pen
Penumbra Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand [Yahoo! Finance]
Low
Report
Penumbra Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand [Yahoo! Finance]
11/6
05:26 pm
pen
Penumbra (NYSE:PEN) had its price target raised by analysts at JPMorgan Chase & Co. from $265.00 to $275.00. They now have a "neutral" rating on the stock.
Low
Report
Penumbra (NYSE:PEN) had its price target raised by analysts at JPMorgan Chase & Co. from $265.00 to $275.00. They now have a "neutral" rating on the stock.
11/6
03:08 pm
pen
Penumbra (NYSE:PEN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Low
Report
Penumbra (NYSE:PEN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
11/6
11:05 am
pen
Penumbra (NYSE:PEN) was given a new $355.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
Penumbra (NYSE:PEN) was given a new $355.00 price target on by analysts at Canaccord Genuity Group Inc..
11/5
04:38 pm
pen
Penumbra, Inc. Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
Penumbra, Inc. Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/5
04:05 pm
pen
Penumbra, Inc. Reports Third Quarter 2025 Financial Results
High
Report
Penumbra, Inc. Reports Third Quarter 2025 Financial Results
11/3
03:00 pm
pen
Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism
Low
Report
Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism
10/27
09:00 am
pen
Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism
Medium
Report
Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism
10/27
08:06 am
pen
Penumbra (NYSE:PEN) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $320.00 price target on the stock.
Low
Report
Penumbra (NYSE:PEN) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $320.00 price target on the stock.
10/27
08:06 am
pen
Penumbra (NYSE:PEN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $326.00 price target on the stock.
Low
Report
Penumbra (NYSE:PEN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $326.00 price target on the stock.
10/15
11:51 am
pen
Penumbra (NYSE:PEN) had its price target lowered by analysts at Truist Financial Corporation from $310.00 to $300.00. They now have a "buy" rating on the stock.
Low
Report
Penumbra (NYSE:PEN) had its price target lowered by analysts at Truist Financial Corporation from $310.00 to $300.00. They now have a "buy" rating on the stock.
10/9
07:15 am
pen
Penumbra (NYSE:PEN) was upgraded by analysts at Needham & Company LLC from a "hold" rating to a "moderate buy" rating.
Low
Report
Penumbra (NYSE:PEN) was upgraded by analysts at Needham & Company LLC from a "hold" rating to a "moderate buy" rating.
10/8
04:30 pm
pen
Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025
Low
Report
Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025
10/8
07:04 am
pen
Penumbra (NYSE:PEN) was given a new $326.00 price target on by analysts at Needham & Company LLC. They now have a "buy" rating on the stock.
Low
Report
Penumbra (NYSE:PEN) was given a new $326.00 price target on by analysts at Needham & Company LLC. They now have a "buy" rating on the stock.
10/7
01:51 pm
pen
Penumbra (NYSE:PEN) had its price target lowered by analysts at Evercore ISI from $300.00 to $285.00. They now have an "outperform" rating on the stock.
Low
Report
Penumbra (NYSE:PEN) had its price target lowered by analysts at Evercore ISI from $300.00 to $285.00. They now have an "outperform" rating on the stock.
10/2
05:45 am
pen
Penumbra, Inc. (PEN) Promotes Shruthi Narayan to President to Drive Global Growth [Yahoo! Finance]
Low
Report
Penumbra, Inc. (PEN) Promotes Shruthi Narayan to President to Drive Global Growth [Yahoo! Finance]
10/1
08:47 am
pen
Penumbra (NYSE:PEN) was given a new $290.00 price target on by analysts at Wells Fargo & Company.
Low
Report
Penumbra (NYSE:PEN) was given a new $290.00 price target on by analysts at Wells Fargo & Company.
9/27
12:38 am
pen
Low
Report
9/18
09:04 am
pen
What Makes Penumbra (PEN) a Good Investment? [Yahoo! Finance]
Low
Report
What Makes Penumbra (PEN) a Good Investment? [Yahoo! Finance]
9/9
09:15 am
pen
New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile [Yahoo! Finance]
Low
Report
New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile [Yahoo! Finance]
9/9
09:00 am
pen
New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile
Low
Report
New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile